The global antiepileptic drug market size was evaluated at USD 18,950 million in 2024 and is expected to grow around USD 29,150 million by 2034, growing at a CAGR of 4.4% from 2024 to 2034.
The antiepileptic drugs market involves developing and manufacturing drugs for epilepsy or convulsions. Drugs that treat epilepsy include phenytoin, carbamazepine, topiramate, levetiracetam, pregabalin, etc. Antiepileptic drugs are available in both oral and parenteral forms. The oral segment is anticipated to hold the major share of the market.
The increasing incidences of epilepsy due to brain infections, head injuries, immune disorders, developmental disorders, and genetics drive the market. The growing research and development activities to develop antiepileptic drugs, as well as increasing investments and collaborations, boost market growth. The rising geriatric population and improved diagnosis capabilities to identify the disease promote market growth. The availability of generic alternatives and the rise in the e-commerce sector and online pharmacies to provide antiepileptic drugs at affordable prices propel market growth.
The future scope of the antiepileptic drugs market includes technological advancements such as artificial intelligence (AI) and machine learning (ML) that revolutionize the research of novel antiepileptic drugs, favorable government support, and new product launches. The growing demand for personalized medicines based on seizure type and unique patient features also offers growth opportunities. Additionally, the increasing number of clinical trials for early detection and treatment of epilepsy potentiate market growth.
Published by Deepa Pandey
